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Significance of this study
What is already known about this subject?
 ► With longer duration of type 2 diabetes, most people 
have a growing need of glucose- lowering medica-
tion and eventually require insulin.
 ► Early treatment of hyperglycemia postpones the in-
dication for insulin treatment.
What are the new findings?
 ► Targeted population- based diabetes screening 
is associated with less need for insulin after 10 
years compared with people diagnosed during 
care- as- usual.
 ► Glycemic control was slightly better after population- 
based screen detection despite less insulin 
prescriptions.
How might these results change the focus of 
research or clinical practice?
 ► The earlier diabetes is diagnosed and an intervention 
is initiated, the more favorable results are possible.
AbStrAct
Introduction With increased duration of type 2 diabetes, 
most people have a growing need of glucose- lowering 
medication and eventually might require insulin. 
Presumptive evidence is reported that early detection 
(eg, by population- based screening) and treatment of 
hyperglycemia will postpone the indication for insulin 
treatment. A treatment legacy effect of population- based 
screening for type 2 diabetes of about 3 years is estimated. 
Therefore, we aim to compare insulin prescription and 
glycemic control in people with screen- detected type 2 
diabetes after 10 years with data from people diagnosed 
with type 2 diabetes seven (treatment legacy effect) and 
10 years before during care- as- usual.
Research design and methods Three cohorts were 
compared: one screen- detected cohort with 10 years 
diabetes duration (Anglo- Danish- Dutch study of Intensive 
Treatment in People with Screen- Detected Diabetes in 
Primary care (ADDITION- NL): n=391) and two care- as- usual 
cohorts, one with 7- year diabetes duration (Groningen 
Initiative to Analyze Type 2 Diabetes Treatment (GIANTT) and 
Zwolle Outpatient Diabetes project Integrating Available Care 
(ZODIAC): n=4473) and one with 10- year diabetes duration 
(GIANTT and ZODIAC: n=2660). Insulin prescription (primary 
outcome) and hemoglobin A1c (HbA1c) of people with a 
known diabetes duration of 7 years or 10 years at the index 
year 2014 were compared using regression analyses.
Results Insulin was prescribed in 10.5% (10- year screen 
detection), 14.7% (7- year care- as- usual) and 19.0% (10- 
year care- as- usual). People in the 7- year and 10- year 
care- as- usual groups had a 1.5 (95% CI 1.0 to 2.1) and 
1.8 (95% CI 1.3 to 2.7) higher adjusted odds for getting 
insulin prescribed than those after screen detection. Lower 
HbA1c values were found 10 years after screen detection 
(mean 50.1 mmol/mol (6.7%) vs 51.8 mmol/mol (6.9%) 
and 52.8 mmol/mol (7.0%)), compared with 7 years and 10 
years after care- as- usual (MDadjusted: 1.6 mmol/mol (95% CI 
0.6 to 2.6); 0.1% (95% CI 0.1 to 0.2) and 1.8 mmol/mol 
(95% CI 0.7 to 2.9); and 0.2% (95% CI 0.1 to 0.3)).
Conclusion Population- based screen- detected type 2 
diabetes is associated with less need for insulin after 10 
years compared with people diagnosed during care- as- 
usual. Glycemic control was better after screen detection 
but on average good in all groups.
InTRoduCTIon
In the Anglo- Danish- Dutch study of Intensive 
Treatment in People with Screen- Detected 
Diabetes in Primary care (ADDITION) study, 
300 000 individuals with a high risk of type 
2 diabetes were screened for type 2 diabetes, 
according to WHO 1999 criteria.1 2 Subse-
quently, in more than 3000 screen- detected 
patients, the effect of an intensive multifacto-
rial treatment (IT) was compared with routine 
care (RC), according to national guidelines.3 
After 5 years, a reduction in fatal and non- 
fatal cardiovascular disease (CVD) of 17% 
(n.s.) was found in favor of the IT group. A 
remarkable result was the finding that 5 years 
after screen detection, 37% and 45% of the 
participants with type 2 diabetes in the IT and 
RC groups did not use any glucose- lowering 
medication.3 After 5 years, the intervention 
stopped, and the subsequent treatment inten-
sity was up to the general practitioner and the 
patient.
Results of two recent post hoc analysis with 
the ADDITION Denmark screening data indi-
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10 years people diagnosed after population- based 
screening had a 21% significant lower risk on all- cause 
mortality and a 16% significant lower risk on CVD events, 
but no significant risk reduction on CVD mortality 
compared with unscreened controls.4 5 Overall, there 
was little benefit that could be directly related to the 
screening programme. In part, this was due to the high 
degree of opportunistic screening in the control group. 
Based on these results, it was suggested that if opportu-
nistic screening has been well established in a health-
care system, population- based screening might not add 
additional health benefits.4 5 In the Netherlands, since 
two decades, general practitioners are recommended to 
screen people with a high risk on type 2 diabetes, during 
surgery hours.6 This opportunistic screening is likely 
established differentially across general practices.7
Targeted population- based screening as well as oppor-
tunistic screening detect people with type 2 diabetes rela-
tively early in the course of their disease. At that time most 
of them will be asymptomatic. Although evidence is avail-
able that early detection is beneficial for disease control, 
the impact of population- based screening compared with 
care- as- usual (including not fully implemented opportu-
nistic screening) needs to be explored.
With increased duration of type 2 diabetes, most people 
have a growing need of glucose- lowering medication and 
eventually require insulin.8 9 According to a computer- 
simulated model based on the ADDITION data, it is 
speculated that the number of people on insulin therapy 
would be much higher if they were diagnosed during 
care- as- usual, an estimated (lead time of) 3–6 years 
later.10 Moreover, presumptive evidence is reported that 
early treatment of hyperglycemia will postpone the indi-
cation for insulin treatment due to possible effects on 
β-cell function.11–13
Hence, we hypothesize that, irrespective of age at diag-
nosis, on the long run, the need for insulin therapy is less 
in people diagnosed with type 2 diabetes during targeted 
population- based screening (like in the ADDITION 
study) compared with people with diabetes diagnosed 
during care- as- usual. Therefore, we evaluated insulin 
prescription and glycemic control in Dutch partici-
pants from the ADDITION study (both IT and RC) 10 
years after being diagnosed with type 2 diabetes. We 
compared these results with data from Dutch people with 
a known diabetes duration of 7 years (assuming a lead 
time of 3 years) and 10 years (since the exact lead time 
is unknown) from two ‘care- as- usual’ diabetes cohorts 
(Groningen Initiative to Analyze Type 2 Diabetes Treat-
ment (GIANTT) and Zwolle Outpatient Diabetes project 
Integrating Available Care (ZODIAC)).14 15
ReseaRCH desIgn and meTHods
subjects
Participants with type 2 diabetes managed by general 
practitioners from three cohorts were included. One 
cohort was the ADDITION- NL cohort (n=391), consisting 
of people diagnosed with type 2 diabetes between 2002 
and 2003 after population- based screening. The two 
remaining cohorts included participants diagnosed with 
type 2 diabetes in usual care with opportunistic screening: 
the GIANTT and ZODIAC14 cohorts (n=3918).15 As 
stated above, opportunistic screening in the Netherlands 
was definitely not yet widely implemented at the start of 
the ADDITION study.15 The guidelines recommended to 
conduct 3 yearly fasting blood glucose testing in people 
aged ≥45 years and one of the following characteristics: 
body mass index (BMI) ≥27 kg/m2, a family history of type 
2 diabetes, being known with hypertension, dyslipidemia 
or CVD, a specific ethnicity (namely Turkish, Moroccan 
or Surinamese) and a history of gestational diabetes. In 
2014, the ADDITION- NL cohort had a diabetes dura-
tion of ~10 years. It was estimated that population- based 
screening would detect people with type 2 diabetes 
approximately 3 years earlier. Therefore, participants 
from the care- as- usual cohorts were divided into two 
groups: people with a known type 2 diabetes duration 
of 7 years (assuming a lead time of 3 years) and 10 years 
(because the exact lead time is unknown), respectively.
ADDITION-NL cohort
The ADDITION- Europe study is a cluster- randomised, 
parallel- group trial evaluating the effect of early IT in 
people with screen- detected type 2 diabetes. The study was 
carried out among 343 general practices in Denmark, the 
UK and the Netherlands. Details of the study have been 
described previously.1 3 ADDITION- NL took place in the 
south western part of the Netherlands, identification of 
high risk for type 2 diabetes took place in all individuals 
aged 50–69 years and unknown with type 2 diabetes. 
High risk for diabetes type 2 was based on the modified 
version of the Symptom Risk Questionnaire used in the 
Hoorn study. The questionnaire contained questions on 
age, sex, BMI, family history of diabetes, frequent thirst, 
use of antihypertensive medication, shortness of breath, 
claudication and cycling. Individuals with a score of ≥4 
points were invited by their general practitioner for 
diabetes assessment, using a random blood glucose test, 
a fasting blood glucose test and an oral glucose tolerance 
test. The WHO 1999 criteria for type 2 diabetes were used 
for diagnosis.1 2
Exclusion criteria were illness with a life expectancy 
less than 1 year and psychiatric disorders invalidating 
informed consent or impeding study participation. 
Practice- level randomization was carried out in 79 general 
practices for providing either care- as- usual, according to 
the 1999 guidelines of the Dutch College of General Prac-
titioners6 or IT according to the ADDITION- NL protocol. 
Randomization was performed according to stratifica-
tion of practice organization (number of patients: 215 IT 
and 176 RC).16 In the 5 years following randomization, 
all patients with screen- detected type 2 diabetes were 
treated according to the randomly allocated treatment 
protocol. General practitioners and nurses in practices 
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motivated during educational meetings up to twice a 
year, for providing strict target- driven pharmacological 
treatment of hyperglycemia as well as promoting healthy 
lifestyles. After 5 years, the trial ended, and after the trial 
period, all patients were most likely treated according to 
the revised Dutch guidelines.17
GIANTT cohort
The GIANTT study started in 2004 in the northern part 
of the Netherlands as a prospective observational study 
for people with type 2 diabetes with the aim to improve 
diabetes care through yearly feedback information and 
advice for participating healthcare professionals. The 
database contains anonymized longitudinal information 
retrieved from electronic medical records of general 
practitioners and is maintained by the University Medical 
Center Groningen.18 These records include medical 
history, prescription data, routine laboratory test results 
and physical examinations of people with type 2 diabetes 
(no age restrictions), who did not opt- out for the use of 
their medical data for scientific research. For scientific 
research with anonymous data, this opt- out regulation is 
offered in the Netherlands as option instead of providing 
full informed consent. Medical history contains date 
of diabetes diagnosis and comorbidity data based on 
the International Classification of Primary Care or text 
descriptions that are coded manually. Data of people 
with a general practitioner- confirmed diagnosis of type 2 
diabetes, exclusively treated in primary care, and a dura-
tion of 7 years or 10 years at the index year 2014 were 
included in the current study.
ZODIAC cohort
The ZODIAC study started in 1998 in the eastern part 
of the Netherlands as a prospective observational study 
for people with type 2 diabetes.19 Study goal was improve-
ment of standard care through addition of extra care-
givers, education and at least yearly feedback information 
and advice for the participating healthcare professionals. 
At inclusion, the individuals participating in the ZODIAC 
study were known with or newly diagnosed with type 2 
diabetes and exclusively treated in primary care; at inclu-
sion, they provided informed consent for the use of their 
anonymized data for research purposes. Individuals 
who were already treated for their diabetes in secondary 
care, individuals with a very short life expectancy and 
individuals with insufficient cognitive abilities were 
excluded. The number of participating general practi-
tioners increased from 53 in 1998 to 459 in 2008. Patient 
numbers increased from 1622 to 27 438 in this time 
frame, and nowadays even more than 40 000 patients are 
participating.
design of the present comparison
Cohort study, with 2014 as index year. Within the three 
cohorts, people were treated according to the same 
national guidelines, with the exception of the ADDI-
TION- IT group. In this group, patients have been treated 
more strictly during the first 5 years after diagnosis. The 
frequency of diabetes monitoring, namely four times per 
year, was equal in all cohorts, all groups and all periods.
Therapy targets
At start of the ADDITION study, hemoglobin A1c 
(HbA1c) levels were targeted at <64 mmol/mol (8.5%) 
and <53 mmol/mol (7.0%) for the RC group and IT 
group, respectively. Moreover, in the IT arm, glucose- 
lowering medication should be started as soon as the 
HbA1c level passed 47 mmol/mol (6.5%). Since 2006, 
the revised Dutch national guidelines set an HbA1c of 
<53 mmol/mol (7%) as target.17 In 2013, less strict targets 
were set for people above 70 years and with a diabetes 
duration longer than 10 years.20
data assessment
Subject characteristics during the index year: age, sex 
and disease control characteristics (HbA1c, lipoproteins 
(serum) – low- density lipoprotein (LDL) cholesterol, 
systolic blood pressure (SBP), BMI and smoking status) 
were all retrieved from the electronic medical records 
of the general practitioners. Assessment dates: GIANTT: 
January–July, ADDITION: January–December, ZODIAC: 
January–December, with value and date of last measure-
ment available in the index period.
glucose-lowering medication
Data of glucose- lowering medication prescribed in the 
index year were collected from the electronic medical 
records of the general practitioners using The Anatom-
ical Therapeutic Chemical Classification System code: 
metformin (A10BA02), sulfonylurea (SU) (A10BB, A10 
BB12 and A10BB09), insulin (A10A), and other oral 
glucose- lowering agents (A10BG, A10BK and A10BJ). 
Glucose- lowering mediation was categorized according to 
the Dutch treatment algorithm, with the following steps: 
(1) lifestyle only; (2) metformin; (3) metformin+SU and 
(4) insulin±oral agents, using other oral blood glucose- 
lowering agents or insulin monotherapy in case of intoler-
ance or contraindications for metformin, SU or insulin.20
outcomes
Primary outcome
The primary outcome was prescription of any insulin 
(either monotherapy or in addition to oral agents) 
during the index year.
Secondary outcome
The secondary outcome was glycemic control (HbA1c 
level) during the index year
statistical analyses
Data of study participants from the former RC and IT 
groups of the ADDITION- NL cohort were merged 
and analyzed as one group. Descriptive statistics were 
performed using SPSS V.24. Categorical variables are 
reported as counts and percentages, continuous variables 
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Table 1 Subject characteristics of the three groups at the index year
ADDITION- NL 
(n=391)
7- years diabetes 
diagnosis (n= 4473)
10- year diabetes 
diagnosis (n= 2660) F- test/χ2 P value
Age (years) 71.6 (5.3) 68.4 (11) 69.7 (10.6) 22.9 <0.01
Sex, male (n, %) 208 (52.7) 2266 (50.5) 1272 (47.8) 6.2 0.04
Smoking, yes (n, %) 52 (14.2) 706 (16.4) 407 (15.9) 1.2 0.55
BMI (kg/m2) 30.4 (6.7) 29.8 (5.3) 29.4 (5.2) 7.1 <0.01
HbA1c (%) 6.7 (0.9) 6.9 (0.9) 7.0 (1.0) NA* NA*
HbA1c (mmol/mol) 50.1 (9.8) 51.8 (10.1) 52.8 (10.4) NA* NA*
SBP (mm Hg) 135 (15.4) 138 (16.1) 138 (16.6) 4.2 0.02
DBP (mm Hg) 74 (9.4) 77 (9.2) 76.1 (9.1) 13.9 <0.01
LDL (mmol/L) 2.1 (0.9) 2.5 (0.9) 2.5 (0.9) 33.7 <0.01
Glucose- lowering medication NA* NA*
  Lifestyle only 72 (18.4) 795 (17.7) 380 (14.3)
  Metformin 116 (29.7) 1501 (33.4) 736 (27.7)
  Metformin+SU 138 (35.3) 1257 (28.0) 848 (31.9)
  Other oral antidiabetic agents 24 (6.1) 275 (6.1) 192 (7.2)
  Metformin and/or SU+insulin 26 (6.6) 492 (11.0) 377 (14.2)
  Insulin monotherapy 12 (3.1) 138 (3.1) 103 (3.9)
  Insulin+other oral diabetic 
agents
3 (0.8) 31 (0.7) 24 (0.9)
*Outcome measures (see table 2).
ADDITION, Anglo- Danish- Dutch study of Intensive Treatment in People with Screen- Detected Diabetes in Primary care; BMI, body mass 
index; DBP, Diastolic Blood Pressure; HbA1c, hemoglobin A1c; LDL, low- density lipoprotein; SBP, systolic blood pressure; SU, sulfonylurea.
distributed variables. Differences with regard to subject 
characteristics between the population- based screening 
and care- as- usual groups were determined by analysis 
of variance for continuous variables and by χ2 tests for 
categorical variables. Logistic regression analysis was 
used to evaluate the difference in insulin prescription 10 
years after screen detection compared with care- as- usual, 
adjusted for the following confounders: age, sex, HbA1c, 
SBP, LDL cholesterol, BMI and smoking, with cohort 
as fixed factor. To determine the differences in HbA1c 
linear regression analyses was used, adjusted for age, sex, 
BMI and glucose- lowering medication according to the 
abovementioned classification. All confounders had <7% 
missing data, except for BMI (10.2% missings) and LDL 
(13.8% missings). To evaluate the impact of missing data, 
we performed multiple imputation, with a 10 imputed 
dataset under the assumption ‘missing at random’ as 
sensitivity analysis. To evaluate the impact of population- 
based screening without the effect of multifactorial inten-
sive treatment during the first 5 years, the ADDITION- NL 
RC group only was compared with the 7 years and 10 
years care- as- usual groups as a sensitivity analysis.
ResulTs
Data of 7524 people with type 2 diabetes and data on 
glucose- lowering medication were included; 391 partic-
ipants had population- based screen- detected diabetes 
(ADDITION- NL cohort) and 7133 people were diagnosed 
with type 2 diabetes during care- as- usual (GIANTT and 
ZODIAC combined): 4473 with 7 years (n=2014 GIANTT, 
n=2459 ZODIAC) and 2660 with 10- year diabetes dura-
tion (n=1201 GIANTT, n=1459 ZODIAC). Subject char-
acteristics of the three groups are presented in table 1. 
People with screen- detected diabetes were on average 
older and more often male compared with people from 
the two other cohorts. Ten years after their screen detec-
tion, people showed a lower SBP (135 mm Hg vs 138 mm 
Hg in both care- as- usual groups) and LDL- cholesterol 
levels (2.1 mmol/L vs 2.5 mmol/L in both care- as- usual 
groups) but a higher BMI: 30.4 kg/m2 vs 29.8 kg/m2 in 
the 7 years and 29.4 kg/m2 in the 10 years group.
Insulin prescription
Insulin prescriptions in people with screen- detected 
diabetes and in people known with diabetes for 7 years 
and 10 years during care- as- usual were 10.5%, 14.8% 
and 19.0%, respectively (table 1). After adjustment for 
confounders, people diagnosed 7 years and 10 years 
before the index year during care- as- usual had a 1.5 (95% 
CI 1.0 to 2.1) and 1.8 (95% CI 1.3 to 2.7) times higher 
chance of getting insulin prescribed compared with 
those with screen- detected diabetes. Similar results were 
found after multiple imputation (table 2). Comparing 
only the ADDITION- NL RC group with the care- as- usual 
groups, the observed point estimates (mean difference) 
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Table 2 Chance in getting insulin prescribed and mean difference in HbA1c for people diagnosed during care- as- usual 
compared with those with screen- detected T2DM
Insulin
ADDITION- NL
7 years 10 years
Crude Adjusted Crude Adjusted
N (%) N (%) OR (95% CI) OR (95% CI) N (%) OR (95% CI) OR (95% CI)
Complete cases 41 (10.5) 661 (14.7) 1.5 (1.1 to 2.1) 1.5 (1.0 to 2.1) 504 (19.0) 2.0 (1.4 to 2.8) 1.8 (1.3 to 2.7)
ADDITION- RC* 17 (9.7) 1.6 (1.0 to 2.7) 1.6 (0.9 to 2.9) 2.2 (1.3 to 3.6) 2.1 (1.2 to 3.7)
MI model† 41 (10.5) 661 (14.7) 1.5 (1.1 to 2.1) 1.5 (1.0 to 2.1) 504 (19.0) 2.0 (1.4 to 2.8) 1.9 (1.3 to 2.7)
HbA1c (%) Mean (SE) Mean (SE) Mean difference (95% CI) Mean (SE) Mean difference (95% CI)
Complete cases 50.1 (0.5) 51.8 (0.2) 1.7 (0.6 to 2.7) 1.6 (0.6 to 2.6) 52.8 (0.2) 2.7 (1.6 to 3.8) 1.8 (0.7 to 2.9)
6.7 (0.05) 6.9 (0.01) 0.2 (0.1 to 0.2) 0.1 (0.1 to 0.2) 7.0 (0.02) 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.3)
ADDITION- RC 50.2 (0.8) 51.8 (0.2) 1.6 (0.0 to 3.1) 1.2 (−0.2 to 2.7) 52.8 (0.2) 2.6 (1.0 to 4.2) 1.5 (−0.0 to 2.9)
6.9 (0.06) 6.9 (0.01) 0.1 (0.0 to 0.3) 0.1 (−0.0 to 0.3) 7.0 (0.02) 0.2 (0.1 to 0.4) 0.1 (−0.0 to 0.3)
MI model† 50.2 (0.8) 51.8 (0.2) 1.7 (0.6 to 2.7) 1.5 (0.5 to 2.5) 52.8 (0.3) 2.7 (1.6 to 3.8) 1.9 (0.9 to 3.0)
6.7 (0.05) 6.9 (0.01) 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.2) 7.0 (0.02) 0.3 (0.2 to 0.4) 0.2 (0.1 to 0.3)
Model on insulin prescription adjusted for age, sex, HbA1c, SBP, LDL- cholesterol, BMI and smoking; model with HbA1c as outcome, 
adjusted for sex, age, BMI and glucose- lowering medication.
*Sensitivity analysis with only care- as- usual group (RC) from ADDITION.
†Sensitivity analysis with multiple imputation.
ADDITION, Anglo- Danish- Dutch study of Intensive Treatment in People with Screen- Detected Diabetes in Primary care ; BMI, body mass 
index; HbA1c, hemoglobin A1c; LDL, low- density lipoprotein; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
resulted in a non- significant OR compared with the 
7 years group (ORadjusted=1.6 (95% CI 0.9 to 2.9). The OR 
compared with the 10 years group (ORadjusted=2.1 (95% CI 
1.2 to 3.7) was larger and remained significant (table 2).
glycemic control
Ten years after their screen detection of type 2 diabetes 
diagnosis, people showed on average a slightly lower 
HbA1c level compared with those with a 7- year and 
10- year diabetes diagnosis based on care- as- usual, namely 
50.1 mmol/mol (6.7%) versus 51.8 mmol/mol (6.9%) 
in those with 7- year and 52.8 mmol/mol (7.0%) with 
10- year diabetes diagnosis. The adjusted mean differ-
ences between people with screen- detected diabetes and 
those diagnosed 7 years and 10 years before during care- 
as- usual were 1.6 mmol/mol (95% CI 0.6 to 2.6) (0.1% 
(95% CI 0.1 to 0.2)) and 1.8 mmol/mol (95% CI 0.7 to 
2.9) (0.2% (95% CI 0.1 to 0.3)), respectively. Similar 
results were found after multiple imputation (table 2). 
Comparing only the ADDITION- NL RC group with the 
care- as- usual groups, the observed mean differences 
remained similar and were borderline significant with 
adjusted mean differences of 1.2 mmol/mol (95% CI −0.2 
to 2.7) (0.1% (95% CI −0.0 to 0.3)) and 1.5 mmol/mol 
(95% CI −0.0 to 2.9) (0.1% (95% CI −0.0 to 0.3) (table 2).
ConClusIon
In this study, we compared 10- year follow- up data after 
population- based diabetes screening with both 7- year and 
10- year follow- up data from care- as- usual. We assumed a 
lead time of 3 years, based on the results of a computer- 
simulated model based on the ADDITION Europe data.8 
Since the exact lead time of population- based screening 
is unknown, we also compared a similar prescribing 
period (10 years). Our results show that population- based 
diabetes screening is associated with less need for insulin 
therapy compared with care- as- usual, which may include 
but does not guarantee opportunistic screening, in combi-
nation with a slightly better long- term glycemic control. 
Although our findings might seem obvious, because 
individuals diagnosed during opportunistic screening 
are likely to have a longer undiagnosed period, they 
are nevertheless clinically relevant. The ADDITION- DK 
study suggested that population- based screening has no 
additional benefits above opportunistic screening on risk 
reduction on CVD mortality.4 5 However, our results indi-
cate that population- based screening might result in a 
delayed need for insulin, which may influence the discus-
sion on population- based versus opportunistic screening 
for type 2 diabetes.
In people with screen- detected type 2 diabetes, the 
HbA1c may be lower compared with opportunistic 
screening and particularly compared with people with 
symptoms of high glucose levels. In a former study, a high 
HbA1c at time of diagnosis was strongly associated with 
early initiation of insulin and poorer glycemic control in 
the future, independent of the selected glucose- lowering 
therapy.21 Therefore, it might be speculated that the 
delayed need for insulin in the screen- detected people 
with type 2 diabetes is at least partially related to a differ-
ence in HbA1c level at time of diagnosis. Unfortunately, 
in the GIANNT and ZODIAC cohorts, data on HbA1c 
at time of diagnosis were not available in the majority 
of patients. The UK Prospective Diabetes Study demon-
strated that a higher glucose level at diagnosis was asso-
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targets and, subsequently, progressive requirement for 
pharmacological treatment.9 22 However, earlier intensive 
treatment is more likely to result in the achievement of 
treatment targets, which are more likely thereafter to be 
maintained. This explanation is in line with the results 
of a retrospective analysis of the UK Clinical Practice 
Research Datalink database Study. This study showed 
that the likelihood of attaining glycemic control was 22% 
and 28% lower for patients in the intermediate (12–<24 
months) and late (24–<36 months) intensification 
groups, respectively, compared with those whose therapy 
had been intensified within 12 months.23
Considering the type of glucose- lowering medication 
prescriptions, according to both the ADDITION protocol 
and the Dutch diabetes guidelines since 2006, metformin 
as well as SU should be prescribed to the maximally 
tolerable dose before insulin is prescribed, taken into 
account a contraindication of metformin for people with 
an estimated glomerular filtration rate (eGFR) <30 mL/
min/1.73 m².20 Our results could also be partly due to a 
difference in prescribing behavior of the physicians in 
the different cohorts, both in terms of type of glucose- 
lowering medication and in dosages. Alternatively, the 
people’s age at the time of diagnosis could also play a 
role; people from the ADDITION- NL cohort were, as a 
result of the inclusion criteria, on average 3 years older 
when they were diagnosed with type 2 diabetes. It could 
be that early detection and a diagnosis of type 2 diabetes 
at older age are associated with a delayed need for 
more intensive treatment. Finally, the method used for 
diagnosing type 2 diabetes differs between the cohorts. 
In the ADDITION- NL cohort, it was based on stepwise 
screening including risk assessment using the Symptom 
Risk Questionnaire, followed by random and/or fasting 
glucose testing and additional an OGTT if needed. In 
the ADDITION- NL cohort, HbA1c has not been used 
as a diagnostic marker. In care- as- usual, about 10% of 
the patients are symptomatic at diagnosis after which a 
random glucose value will suffice according to the guide-
lines from the Dutch College of General Practitioners. 
In the vast majority of asymptomatic people who are 
diagnosed with type 2 diabetes by care- as- usual, at least 
one fasting glucose measure in a certified laboratory will 
have been taken. According to the above- mentioned 
guidelines, general practitioners were not advised to use 
HbA1c as a diagnostic marker. Altogether, however, the 
different diagnosing strategies all result in a diagnosis 
of diabetes that is considered reliable. So, whereas the 
diagnostic process and the HbA1c level at diagnosis will 
likely to be different between the cohorts, they are intrin-
sically linked to the difference between population- based 
screening and care- as- usual. Therefore, adjusting for 
these factors would not be justified, and the results of this 
study allow conclusions based on the time of detection.
Strengths of this study are the availability of detailed 
data on glycemic control and glucose- lowering medica-
tion over a follow- up period of 10 years after population- 
based screen detection of type 2 diabetes and data from 
care- as- usual from the same healthcare system. Several 
limitations should be mentioned. First, the design of our 
study does not allow causal interpretation; we adjusted 
for some patient differences, but bias and confounding 
are possible. Second, we included three Dutch cohorts 
from different regions with may be different patients’ 
socioeconomic status, ethnicity and willingness to partic-
ipate. Finally, we assumed a lead time of 3 years with 
population- based screen detection, but the higher age at 
diagnosis in the ADDITION- NL cohort suggests this may 
not be true.
In conclusion, 10 years after screen- detected type 2 
diabetes according to WHO criteria, a lower number of 
people are in need of insulin compared with individuals 
diagnosed during care- as- usual, in combination with a 
slightly better glycemic control. This suggests that the 
earlier diabetes is diagnosed and an intervention is initi-
ated, the more favorable results are possible.
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